key: cord-0752484-y3kgyzfz
authors: Dimeglio, Chloé; Herin, Fabrice; Martin-Blondel, Guillaume; Miedougé, Marcel; Izopet, Jacques
title: Antibody titers and protection against a SARS-CoV-2 infection
date: 2021-09-21
journal: J Infect
DOI: 10.1016/j.jinf.2021.09.013
sha: 43204db11472ca2b39e2913afd080d3d82d4afbe
doc_id: 752484
cord_uid: y3kgyzfz

nan

Recent studies indicate that binding and neutralizing SARS-CoV-2 antibodies elicited by natural infection or vaccination persist for more than 6 months although their concentration decreases over time [1] . The passive transfer of neutralizing antibodies (NAb) and protection are correlated in non-human primates [2] . While such a link has not yet been defined in humans, individuals with a high NAb titer could well be better protected against SARS-CoV-2.

A recent letter in Journal of Infection indicated that indeed neutralizing antibodies are considered linked to protective immunity due to their ability to block the viruses from entering the host cells. The authors discussed the decrease in neutralizing antibodies after vaccination without being able to provide a threshold below which protection against SARS-CoV-2 infection is no longer guaranteed [3] .

We measured the antibody titers in 8,758 healthcare workers (HCWs), vaccinated and unvaccinated, soon after the first epidemic wave had occurred in France (10 June-10 July, 2020). Total SARS-CoV-2 antibodies were measured in longitudinal samples with a quantitative enzyme-linked immunosorbent assay (ELISA) (Wantai Biological Pharmacy Enterprise Co., Ltd, China) and a live-virus neutralization assay using Vero cells and a B.1.160 strain (GISAID EPI-ISL-804372) [4] . Symptomatic and asymptomatic infections were detected with a nucleic-acid amplification method (Aptima TM SARS-CoV-2 assay, Panther TM system, Hologic, USA) [5] . This study was approved by the French Research Ethics Committee Est-III (COVID BioToul, ID-RCB 2020-A01292-37, ClinicalTrials.gov Identifier: NCT04385108).

The median age of the 8,758 HCWs (7,039; 80.4% females) was 40 years (interquartile range

[IQR] 32-50). Over half of them (4,811; 54.9%) had been given one (2,244; 46.6%) or two [6] and the neutralizing antibody titers from July ELISA total antibody concentrations indicated that 12.1% [95 % CI: 11.5% -12.8%] of HCWs with a negative ELISA or an ELISA concentration below 13 BAU/ml became infected between July 2020 and April 2021, as did 10.6% [95 % CI: 6.5% -16.1%] of HCWs that had an ELISA concentration between 13 and 141 BAU/ml. In contrast only 1.3% [95 % CI: 0.03% -7.2%] of those with an ELISA concentration between 141 and 1,700 BAU/ml became infected and none of those with an ELISA concentration of 1,700 BAU/ml and above (p<0.01, Chi2 test).

Analysis of all the data indicated that a NAb titer well below 64 provided 76.8% protection against SARS-CoV-2, a titer of 64 to 128 gave 94% protection and a NAb titer of 256 or more provided full (100%) protection (Figure 2A ). In the same way, an ELISA concentration between 13 and 141 BAU/ml provided only 12.4% protection against SARS-CoV-2, a concentration between 141 and 1,700 BAU/ml provided 89.3% protection and a concentration of 1,700 BAU/ml and above provided full protection ( Figure 2B ). In our cohort, none of the two doses-vaccinated HCWs had an ELISA concentration below 141 BAU/ml one month after the second injection, unlike 79.3% of the HCWs three months after a natural infection.

Our study did not assess cell-mediated immunity and all the subjects were HCWs. However, the data suggest that monitoring the neutralizing antibody response but also total antibody concentrations, logistically more feasible, can be used to optimize vaccination strategies by estimating the duration and degree of protection provided by vaccines. The thresholds of protection found in our study should be compared to those obtained in further studies on other populations. It is also essential to estimate the influence of an antibody's reduced neutralizing capacity against new emerging viruses variants [7, 8] . 

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Correlates of protection against SARS-CoV-2 in rhesus macaques

Post-SARS-CoV-2 vaccination specific antibody decrease -Thresholds for determining seroprevalence and seroneutralization differ

Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France

Evaluation of the Aptima™ transcriptionmediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens

The CEPI centralised laboratory network: supporting COVID-19 vaccine development

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

The English text was edited by Dr Owen Parkes.

The authors declare no conflict of interest